Forum
- PDF / 66,792 Bytes
- 3 Pages / 581 x 791 pts Page_size
- 68 Downloads / 136 Views
Pharm Med 2008; 22 (2): 127-129 1178-2595/08/0002-0127/$48.00/0 © 2008 Adis Data Information BV. All rights reserved.
Forum Contents 1. 2. 3. 4. 5. 6. 7. 8.
Call for Greater Global Dissemination of Clinical Science . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127 Investment in Genetic Research Pays Off . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127 Reviving Serendipity in Drug Discovery a “Utopian Fantasy”? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127 Pharma Industry Less than Healthy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128 MACE an Unreliable Endpoint in Cardiovascular Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128 Ethics of Clinical Trials called into Question . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128 Mandatory Trial Results Disclosure has Implications for Journals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129 UK Yellow Card Scheme: Pharmacists to Encourage Patient Reporting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
1. Call for Greater Global Dissemination of Clinical Science “There is more need for clinical science of international interest to be globally disseminated”, conclude researchers from Greece and the US. The researchers evaluated data concerning the country of origin of studies published in 11 leading medical journals over a period of 35 years. The Lancet demonstrated the most diversity regarding the origin of published studies; between 1971 and 1975, 62.6% of studies published in this journal were from the UK, whereas between 2001 and 2005 only 43.2% of published studies were from the UK. For the remaining journals, the proportion of articles published that originated from the country in which the journal is based ranged between 71.7% and 95.1%, for the period 2001–5. “We strongly believe that further efforts to boost the globalisation of the research published in the major biomedical journals will be a service to the global biomedical community as well as the public”, contend the researchers. Falagas ME, Alexiou VG. An analysis of trends in globalisation of origin of research published in major general medical journals. Int J Clin Pract 2008 Jan; 62 (1): 71-5
2. Investment in Genetic Research Pays Off “Landmark genetic discoveries yield positive randomized, controlled trials and approved treatments frequently enough to justify investments into genetic research”,
